<DOC>
	<DOCNO>NCT01290419</DOCNO>
	<brief_summary>A Phase 1 , Randomized , Placebo-Controlled , Observer-Blinded , Escalating Dose-Ranging Study Assess Safety , immunogenicity 6 different recombinant RSV-F formulation healthy adult ( 18 49 year age ) . Study Objectives : Primary : - To assess compare safety , reactogenicity , tolerability 6 RSV-F protein particle vaccine formulation . Secondary : - To assess compare immunogenicity ( neutralize antibody total anti-F antibody ) 6 RSV-F protein particle vaccine formulation - To confirm `` dose sparing '' `` value add '' effect aluminum phosphate adjuvant</brief_summary>
	<brief_title>Safety Study Respiratory Syncytial Virus ( RSV ) -Fusion ( F ) Protein Particle Vaccine</brief_title>
	<detailed_description>A total 150 subject allocate 7 cohort . Subjects randomly assign vaccine treatment saline placebo 4:1 ratio , cohort include 20 subject receive active vaccine ( Groups A , B , C , D , F G ) 5 subject receive placebo ( Group E ) . Subjects followed AEs , include SAEs non-serious AEs , time vaccination 30 day follow second vaccination ( Day 60±5 ) . After Day 60 , subject contact via telephone monthly basis ( approximately Days 90 , 120 , 150 , 180 , 210 ) ask occurrence SAEs SNMCs .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 49 year inclusive Ability provide write informed consent participate Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination baseline Females require fulfill one follow criterion : At least 1 year postmenopausal Surgically sterile Willing use oral , implantable , transdermal injectable contraceptive 30 day prior first vaccination 28 day vaccination Willing abstain sexual intercourse use another reliable form contraception approve Investigator ( eg , intrauterine device , female condom , diaphragm spermicide , cervical cap , use condom sexual partner , sterile sexual partner ) study duration 28 day vaccination All female subject must negative urine pregnancy test within 48 hour precede receipt vaccination . Comprehension study requirement , express availability require study period , ability attend schedule visit contact telephone throughout followup period Presence significant uncontrolled medical psychiatric illness ( acute chronic ) . This include institution new medical surgical treatment , significant dose alteration uncontrolled symptom drug toxicity within 3 month screen reconfirm Day 1 prior vaccination Positive serology HIV1 HIV2 , HBsAg HCV antibody Pregnant lactate female Females plan become pregnant plan discontinue contraceptive precaution within 30 day prior first vaccination 28 day vaccination Cancer , treatment cancer , within 3 year , exclude basal cell carcinoma squamous cell carcinoma , allow Presence medical condition may associate impaired immune responsiveness , include diabetes mellitus Receipt ( history receipt ) , precede 3month period , medication treatment may adversely affect immune system allergy injection , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) . Inhaled topical corticosteroid allow . Receipt plan administration nonstudy vaccine within 30 day prior vaccination study . If nonstudy vaccine administer , administration study vaccine injection delay give soon allowable within 30day window , provide nonstudy vaccine administer within 2 week prior study enrollment . Immunization Tetanus Toxoids Adsorbed adult use ( Td Tdap ) vaccine , emergency basis , 8 day least 8 day dose study vaccine allow . History illicit drug alcohol abuse within previous 1 year positive drug alcohol screen History anaphylactic type reaction inject vaccine Receipt investigational product nonregistered drug within 30 day prior vaccination current enrollment investigational drug study intent enroll study within ensue study period Receipt donation blood blood product 8 week prior vaccination plan receipt donation study period Acute disease , define presence moderate severe illness ( determined Investigator medical history physical examination ) without fever , oral temperature ≥38ºC , within 72 hour prior vaccination . Study vaccine administer person minor illness , diarrhea mild upper respiratory tract infection without lowgrade fever . Vaccination delay subject recover . Any condition , opinion Investigator , would interfere primary study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>RSV</keyword>
</DOC>